-The Hindu Chronic corruption and lack of affordable access to treatments for serious diseases in the public health system stand exposed in the kidney commerce scandal in Tamil Nadu's Dharmapuri district. Nothing can be a greater irony than the existence of such thriving sale of organs in a State that also has perhaps the best-run programme for donation of kidneys, livers, hearts and lungs by deceased donors. It is no small...

-The Business Standard Angelina Jolie has inadvertently highlighted a key question about patenting Angelina Jolies recent double mastectomy was obviously a very radical decision. It is unusual for a healthy person to opt for pre-emptive surgery to avert the probability, however high it may be, of getting cancer. The tests Jolie relied on are also at the heart of a legal battle, which could affect US biotech patenting norms. Since the US...

-The Telegraph About half of Delhi's police personnel are overweight and have high blood pressure or cholesterol, heart problems, diabetes, insomnia or weak eyesight, a health camp has found out. Senior officers declined comment but their juniors, requesting anonymity, blamed overwork and stress. An internal police report says that 48 per cent among the 2,000 who participated in the 19-day camp were overweight and had high cholesterol. Over a third - 34 per...

-The Business Standard Court denies Swiss drug firm patent protection for its anti-cancer drug Glivec; domestic industry hails verdict The Supreme Court on Monday dismissed Novartis AG's appeal for patent protection of its anti-cancer drug, Glivec, putting an end to a seven-year battle between the Swiss drug maker, several domestic generic manufacturers, as well as patient groups fighting for affordable medicines. A Bench of judges Aftab Alam and Ranjana Desai said in a...

-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster...